OptiBiotix commercial progress for LP-LDL & SlimBiome Cholesterol, hypertension and weight management. SlimBiome is a multi award winner
Small Companies – £300k + pa (EACH) THWLC (GoFigure) SlimBiome (May 2017) HLH BioPharma – LP-LDL (May 2017) Germany and EU PharmaBiota – LP-LDL (September 2017) New Zealand & Australia
Medium Companies – £500k to £1m pa (EACH) Nutrilinea – LP-LDL (May 2017) EU Knightons – SlimBiome (November 2017) UK Cambridge Commodities – SlimBiome (April 2018) UK & EU Seed Health – LP-LDL (TBC)
Large Companies £1.5m + pa (EACH) SACCO – LP-LDL (August 2017) Global Galenicum – LP-LDL (October 2017) EU, Middle East, Japan, America's Cereal Ingredients Inc – SlimBiome (December 2018) USA TATA – SlimBiome (December 2016) ASIA TATA – LP-LDL (September 2017) India & Asia Tigren pharmaceuticals – LP-LDL (April 2018) Pakistan FineFoods & Pharmaceuticals -LP-LDL (March 2018) EU AKUMS – LP-LDL + LP-LDL pharmaceutical (May 2018) India & South Asia
Undisclosed US partner – SlimBiome (TBC) 3 large UK Retailers – (TBC) these could yield **£5m – £6m pa 2 global corps interested in using SweetBiotix Bened MOU cross partnership IP Asia & EU, USA
PLC costs under £1m pa – DO THE MATH Using below industry valuations of 10 time earning, for fun only, tweet a reply with your future valuation. I dare you!! :–)
Note: No additional cash injection required from OptiBiotix as commercial ramp up progresses.
The market is missing a significant NEW development with AKUMS announcement. As well as OTC products, AKUMS has the option to take OPTI LP-LDL IP down the pharma route. Given OPTI platform is pharma based and phase 3 ready, this save 6-8 years R&D saving millions in the process.
It's no coincidence these last 3 commercial agreements have been with pharma companies with a who's who client list within the pharma industry; Abbott, Novartis, P&G, Pfizer, Bayer, Sanofi and Sandoz.
IMHO these routes offer discrete back-door route to pharma commercial agreements.